New York, New York (PRWEB) August 02, 2014
Risperdal lawsuits (http://www.lawreward.com/risperdal-lawsuit/) that allege use of the antipsychotic medication caused men and boys to develop gynecomastia, or male breast growth, continue to mount in U.S. courts, Bernstein Liebhard LLP reports. According to court documents dated July 8th, one such case has been filed in U.S. District Court, Northern District of New York, on behalf of a 21-year-old man who underwent multiple surgeries to remove excess breast tissue after he developed gynecomastia that was allegedly caused by Risperdal. The complaint further claims that the Plaintiff’s treatment with the medication for several years also caused him to begin lactating. The new Risperdal lawsuit seeks compensation for severe, painful, disabling and permanent injuries, as well as emotional problems allegedly endured by the Plaintiff. (Case 1:14-cv-00820-GTS-RFT)
“Our Firm is representing a number of clients whose experience with this medication echo the allegations put forth in this latest Risperdal lawsuit filing,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Risperdal Gynecomastia Litigation
Court documents indicate that hundreds of plaintiffs are currently pursuing Risperdal lawsuits for gynecomastia allegedly caused by the medication. The majority of these claims are pending in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas. Among other things, the complaints accuse Johnson & Johnson and Janssen of concealing the association between Risperdal and male breast growth, and of improperly marketing the drug for off-label use in children. (In Re: Risperdal Litigation, Case Number 100300296).
On November 4th, the U.S. Department of Justice announced that Johnson & Johnson and Janssen had agreed to pay $2.5 million to resolve criminal and civil charges stemming from their marketing of Risperdal and other drugs. Among other things, federal prosecutors had alleged that the companies marketed Risperdal for pediatric uses long before it was approved for such indications in 2006. According to court documents filed in the case, the Justice Department had also charged that the company concealed side effects associated with the medication, including an association between Risperdal and male breast growth. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Alleged victims of Risperdal and gynecomastia may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com